Published in Expert Opin Biol Ther on November 01, 2010
Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer (2014) 1.48
Natural and induced T regulatory cells in cancer. Front Immunol (2013) 1.15
CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol (2012) 1.06
Peripheral and thymic foxp3(+) regulatory T cells in search of origin, distinction, and function. Front Immunol (2013) 1.02
Functions of thymic stromal lymphopoietin in immunity and disease. Immunol Res (2012) 1.00
Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP. Oncotarget (2015) 0.99
Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLoS One (2013) 0.96
Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther (2014) 0.93
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) (2014) 0.92
Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother (2013) 0.89
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal (2012) 0.88
Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results. J Exp Clin Cancer Res (2013) 0.83
Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother (2012) 0.83
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel) (2016) 0.82
The role of regulatory T cells in cancer immunology. Immunotargets Ther (2015) 0.82
The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients. Exp Hematol Oncol (2014) 0.81
Helios Should Not Be Cited as a Marker of Human Thymus-Derived Tregs. Commentary: Helios(+) and Helios(-) Cells Coexist within the Natural FOXP3(+) T Regulatory Cell Subset in Humans. Front Immunol (2016) 0.80
Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. Cancer Microenviron (2014) 0.80
Neem components as potential agents for cancer prevention and treatment. Biochim Biophys Acta (2014) 0.80
Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. Oncotarget (2016) 0.80
Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch (2012) 0.79
TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy. Oncoimmunology (2012) 0.79
FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. Prostate (2017) 0.75
Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. J Circ Biomark (2016) 0.75
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol (2010) 9.72
CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med (2008) 2.72
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother (2005) 1.50
Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol (2013) 1.49
Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood (2012) 1.36
Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. Osteoarthritis Cartilage (2005) 1.34
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother (2007) 1.32
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
The critical contribution of TGF-beta to the induction of Foxp3 expression and regulatory T cell function. Eur J Immunol (2008) 1.30
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol (2010) 1.25
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res (2006) 1.24
O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull (2008) 1.21
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14
Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther (2010) 1.10
Cancer vaccines and immunotherapy. Br Med Bull (2002) 1.07
Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9. Tissue Eng (2004) 1.04
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res (2009) 1.04
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother (2008) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev (2014) 1.03
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br J Haematol (2008) 1.02
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol (2005) 1.00
The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol (2010) 0.99
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol (2010) 0.99
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother (2012) 0.98
T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol (2007) 0.98
Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol (2011) 0.95
Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother (2002) 0.95
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int J Cancer (2014) 0.95
Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial. PLoS One (2012) 0.95
Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta (2004) 0.93
Functional expression of secreted proteins from a bicistronic retroviral cassette based on foot-and-mouth disease virus 2A can be position dependent. Hum Gene Ther (2010) 0.93
Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res (2007) 0.93
Lactobacillus reuteri DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis. PLoS One (2013) 0.92
Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol (2012) 0.92
Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int J Cancer (2012) 0.92
Sam68 modulates the promoter specificity of NF-κB and mediates expression of CD25 in activated T cells. Nat Commun (2013) 0.90
Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother (2009) 0.90
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol (2006) 0.90
Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther (2015) 0.89
An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother (2008) 0.89
Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. Leuk Lymphoma (2013) 0.88
Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther (2005) 0.87
Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer (2004) 0.87
High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother (2011) 0.86
Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opin Biol Ther (2008) 0.86
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother (2007) 0.85
Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis. Cytometry A (2010) 0.85
Tumor infiltrating regulatory T cells: tractable targets for immunotherapy. Int Rev Immunol (2010) 0.85
Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother (2009) 0.85
Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother (2014) 0.85
Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum (2003) 0.84
Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors. J Gene Med (2010) 0.84
Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding. Mol Ther (2010) 0.84
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol (2007) 0.84
Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum Gene Ther Methods (2013) 0.84
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy. Cancer Immunol Immunother (2011) 0.84
CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer (2006) 0.83
Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology (2006) 0.83
Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol (2002) 0.83
A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing? Pancreas (2006) 0.82
Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. J Immunol (2014) 0.82
Amplification of epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer (2010) 0.81
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother (2011) 0.81
Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev (2006) 0.81
Rapid high-performance liquid chromatographic analysis of adenovirus type 5 particles with a prototype anion-exchange analytical monolith column. J Chromatogr A (2008) 0.80
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. Cancer Immunol Immunother (2013) 0.80
5T4 as a target for immunotherapy in renal cell carcinoma. Expert Rev Anticancer Ther (2009) 0.80
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. Oncology (2014) 0.80
Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein? Breast Cancer Res (2012) 0.79
CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells. Cancer Immunol Immunother (2007) 0.79
TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice. Cancer Immunol Immunother (2015) 0.78
In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert Opin Pharmacother (2014) 0.77